The clinical analysis of insulin glargine combined repaglinide in treatment of type 2 diabetes

OBJECTIVE To discuss the clinical efficacy and value of insulin glargine combined repaglinide in treatment of type 2 diabetes.METHODS 84 patients with type 2 diabetic patients were randomly divided into observation group and control group,the observation group was treated with subcutaneous injection of insulin glargine combined the oral treatment of repaglinide,the control group was treated with subcutaneous injection therapy of premixed insulin,observed FPG,2hPG,HbA1C levels,the amount of insulin and hypoglycemia rates in two groups of patients before and after treatment.RESULTS After treatment,FPG,2hPG,HbA1C levels in two groups after treatment were significantly lower than before treatment(P ﹤ 0.05) ;HbA1C level after treatment in the control group was significantly lower than in the observation group(P ﹤ 0.05) ;insulin dosage of(18.35 ± 4.56) U /d in the observation group was significantly lower than that(34.26 ± 6.51) U /d in the control group(P﹤0.05);the incidence of hypoglycemia in the observation group during treatment was significantly lower than in the control group(P﹤0.05).CONCULSION Glargine insulin plus repaglinide in the treatment of type 2 diabetes can reduce the incidence of low blood sugar while maintaining stable blood glucose and reduce the amount of insulin,which is a better option in the treatment of type 2 diabetes and worthy of clinical application.